These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9365330)

  • 1. Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.
    Agaliotis DP; Ballester OF; Mattox T; Hiemenz JW; Fields KK; Zorsky PE; Goldstein SC; Perkins JB; Rosen RM; Elfenbein GJ
    Am J Med Sci; 1997 Nov; 314(5):292-8. PubMed ID: 9365330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
    Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE
    J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Meisenberg BR
    J Clin Oncol; 1995 Jul; 13(7):1826-7. PubMed ID: 7602373
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
    Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation.
    Elborai Y; Almutereen M; Maher OM; Hafez H; Lee MA; Lehmann L
    J Egypt Natl Canc Inst; 2020 Feb; 32(1):9. PubMed ID: 32372349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous toxicity of high-dose carboplatin, etoposide and ifosfamide followed by autologous stem cell reinfusion.
    Beyer J; Grabbe J; Lenz K; Weisbach V; Strohscheer I; Huhn D; Siegert W
    Bone Marrow Transplant; 1992 Dec; 10(6):491-4. PubMed ID: 1362685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation.
    Oblon DJ; Paul SR; Oblon MB; Malik S
    Bone Marrow Transplant; 1997 Dec; 20(11):961-3. PubMed ID: 9422475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Lotz JP; Izrael V
    Bone Marrow Transplant; 1995 Dec; 16(6):858-9. PubMed ID: 8750286
    [No Abstract]   [Full Text] [Related]  

  • 17. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
    Caglar K; Kinalp C; Arpaci F; Turan M; Saglam K; Ozturk B; Komurcu S; Yavuz I; Yenicesu M; Ozet A; Vural A
    Nephrol Dial Transplant; 2002 Nov; 17(11):1931-5. PubMed ID: 12401849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
    Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
    Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia.
    Gerke P; Filejski W; Robins HI; Wiedemann GJ; Steinhoff J
    J Cancer Res Clin Oncol; 2000 Mar; 126(3):173-7. PubMed ID: 10741912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.